<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN" "http://jats.nlm.nih.gov/publishing/1.1/JATS-journalpublishing1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="research-article" dtd-version="1.1">
<front>
<journal-meta>
<journal-id journal-id-type="pmc">BIOCELL</journal-id>
<journal-id journal-id-type="nlm-ta">BIOCELL</journal-id>
<journal-id journal-id-type="publisher-id">BIOCELL</journal-id>
<journal-title-group>
<journal-title>BIOCELL</journal-title>
</journal-title-group>
<issn pub-type="epub">1667-5746</issn>
<issn pub-type="ppub">0327-9545</issn>
<publisher>
<publisher-name>Tech Science Press</publisher-name>
<publisher-loc>USA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">20198</article-id>
<article-id pub-id-type="doi">10.32604/biocell.2022.020198</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Immune-related DNA methylation signature associated with APLN expression predicts prognostic of hepatocellular carcinoma</article-title><alt-title alt-title-type="left-running-head">Immune-related DNA methylation signature associated with APLN expression predicts prognostic of hepatocellular carcinoma</alt-title><alt-title alt-title-type="right-running-head">APLN combined with methylation predicts prognosis</alt-title>
</title-group>
<contrib-group content-type="authors">
<contrib id="author-1" contrib-type="author">
<name name-style="western"><surname>TIAN</surname><given-names>FEIFEI</given-names></name>
<xref ref-type="aff" rid="aff-1">1</xref>
</contrib>
<contrib id="author-2" contrib-type="author">
<name name-style="western"><surname>HU</surname><given-names>HUAN</given-names></name>
<xref ref-type="aff" rid="aff-1">1</xref>
</contrib>
<contrib id="author-3" contrib-type="author">
<name name-style="western"><surname>WANG</surname><given-names>DI</given-names></name>
<xref ref-type="aff" rid="aff-1">1</xref>
</contrib>
<contrib id="author-4" contrib-type="author">
<name name-style="western"><surname>DING</surname><given-names>HUAN</given-names></name>
<xref ref-type="aff" rid="aff-1">1</xref>
</contrib>
<contrib id="author-5" contrib-type="author">
<name name-style="western"><surname>CHI</surname><given-names>QINGJIA</given-names></name>
<xref ref-type="aff" rid="aff-2">2</xref>
</contrib>
<contrib id="author-6" contrib-type="author">
<name name-style="western"><surname>LIANG</surname><given-names>HUAPING</given-names></name>
<xref ref-type="aff" rid="aff-3">3</xref>
</contrib>
<contrib id="author-7" contrib-type="author" corresp="yes">
<name name-style="western"><surname>ZENG</surname><given-names>WENLI</given-names></name>
<xref ref-type="aff" rid="aff-4">4</xref>
<email>Zengwenli600@163.com</email>
</contrib>
<aff id="aff-1"><label>1</label><institution>School of Life Science and Engineering, Southwest Jiaotong University</institution>, <addr-line>Chengdu, 610000</addr-line>, <country>China</country></aff>
<aff id="aff-2"><label>2</label>Department of Engineering Structure and Mechanics, School of Science, Wuhan University of Technology, Wuhan, 430070, China</aff>
<aff id="aff-3"><label>3</label>State Key Laboratory of Trauma, Burns and Combined Injury, Research Institute of Surgery, Daping Hospital, The Army Medical University, Chongqing, 400042, China</aff>
<aff id="aff-4"><label>4</label>Renmin Hospital of Wuhan University Nursing Department, Wuhan, 430070, China</aff>
</contrib-group><author-notes><corresp id="cor1"><label>&#x002A;</label>Address correspondence to: Wenli Zeng, <email>Zengwenli600@163.com</email></corresp></author-notes>
<pub-date pub-type="epub" date-type="pub" iso-8601-date="2022-06-09"><day>09</day>
<month>06</month>
<year>2022</year></pub-date>
<volume>46</volume>
<issue>10</issue>
<fpage>2291</fpage>
<lpage>2301</lpage>
<history>
<date date-type="received"><day>18</day><month>11</month><year>2021</year></date>
<date date-type="accepted"><day>11</day><month>2</month><year>2022</year></date>
</history>
<permissions>
<copyright-statement>&#x00A9; 2022 Tian et al.</copyright-statement>
<copyright-year>2022</copyright-year>
<copyright-holder>Tian et al.</copyright-holder>
<license xlink:href="https://creativecommons.org/licenses/by/4.0/">
<license-p>This work is licensed under a <ext-link ext-link-type="uri" xlink:type="simple" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution 4.0 International License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
</license>
</permissions>
<self-uri content-type="pdf" xlink:href="TSP_BIOCELL_20198.pdf"></self-uri>
<abstract>
<p>This study used transcriptome and epigenetic data to predict the prognosis of immune-related genes (IRGs) Apelin (APLN) in patients with hepatocellular carcinoma (HCC). The TCGA database has gene expression and clinical data for HCC. And DNA methylation 450 k data for HCC was download from the University of California Santa Cruz (UCSC) Xena browser. Performing clinical and prognostic analysis of APLN expression, results show that APLN is highly expressed in tumor samples. And it has an increasing trend with the development of clinical stage and T stage. To explore the prognostic role of APLN, the Immune-related DNA methylation (DNAm) sites associated with APLN analyzed by bioinformatics. Univariate COX screened the methylation sites that are related to both APLN and survival. The risk score related to methylation site signature was determined according to their least absolute shrinkage and selection operator (LASSO) coefficients. Then the patients were divided into high-risk groups and low-risk groups. Significant differences in overall survival (OS) were found in the training cohort. Nomogram shows that APLN or methylation signature can effectively predict the prognosis of HCC patients. In summary, APLN may be a diagnostic and prognostic marker for HCC.</p>
</abstract>
<kwd-group kwd-group-type="author">
<kwd>TIME</kwd>
<kwd>Immunity</kwd>
<kwd>Prognosis</kwd>
<kwd>Bioinformatics</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="s1">
<title>Introduction</title>
<p>Hepatocellular carcinoma is one of the common primary tumors, causing more than 700,000 deaths each year. Tobacco, heredity, epigenetic factors will affect its development. Although many detection and treatment methods of computer tomography (CT) and emerging carbon ion radiation have made good progress (<xref ref-type="bibr" rid="ref-33">Malouff <italic>et al</italic>., 2020</xref>). HCC patients are prone to recurrence and metastasis of hemangioma after surgery or ablation, causing the poor prognosis (<xref ref-type="bibr" rid="ref-27">Korean Liver Cancer Association and National Cancer Center, 2019</xref>; <xref ref-type="bibr" rid="ref-6">Brown <italic>et al</italic>., 2019</xref>; <xref ref-type="bibr" rid="ref-38">Muto <italic>et al</italic>., 2014</xref>). Currently, the study&#x2019;s diagnostic markers are limited and only for some populations (<xref ref-type="bibr" rid="ref-43">Rawat <italic>et al</italic>., 2018</xref>). Therefore, it is of great significance to study specific diagnostic biomarkers to predict the survival and diagnosis of HCC.</p>
<p>Epigenetic regulation does not change DNA sequence but changes the transcription mechanism and affects the tumor&#x2019;s progress (<xref ref-type="bibr" rid="ref-46">Sharma <italic>et al</italic>., 2020</xref>; <xref ref-type="bibr" rid="ref-13">Dzobo <italic>et al</italic>., 2020</xref>; <xref ref-type="bibr" rid="ref-4">Baylin and Jones, 2011</xref>). Among them, DNA methylation (5-methylcytosine DNAm, m5C) and RNA methylation (6-methyladenine RNAm, m6A) are two crucial nucleic acid modifications, which are epigenetic important regulation mechanism (<xref ref-type="bibr" rid="ref-31">Liu and He, 2020</xref>). DNAm modification affects gene transcription (alternative splicing or translation), leading to abnormal gene expression and causing diseases. DNA methylation sites were served as prognostic markers in colorectal cancer and kidney cancer with high sensitivities, <italic><italic>e.g</italic>.</italic>, cg10673833 and cg04448376 (<xref ref-type="bibr" rid="ref-32">Luo <italic>et al</italic>., 2020</xref>; <xref ref-type="bibr" rid="ref-52">Wang and Zhang, 2020</xref>; <xref ref-type="bibr" rid="ref-21">Ibrahim <italic>et al</italic>., 2011</xref>; <xref ref-type="bibr" rid="ref-2">Ashokan <italic>et al</italic>., 2021</xref>). Compared with a single omics biomaker to explore HCC prognosis, the strategy combining DNA methylation data and transcriptomics&#x2019; data is believed to be more promising.</p>
<p>The APLN gene locates on chromosome Xq25-q26.1 and can encode 77 amino acid pro-peptide Apelin (<xref ref-type="bibr" rid="ref-57">Xu <italic>et al</italic>., 2017</xref>). APLN may be a potential marker in ovarian cancer, colorectal cancer, kidney cancer and other cancers (<xref ref-type="bibr" rid="ref-10">Chen <italic>et al</italic>., 2021</xref>; <xref ref-type="bibr" rid="ref-42">Ran <italic>et al</italic>., 2021</xref>; <xref ref-type="bibr" rid="ref-3">Bai <italic>et al</italic>., 2020</xref>; <xref ref-type="bibr" rid="ref-62">Zuurbier <italic>et al</italic>., 2017</xref>). Not only can APLN gene activate the pathway of APLN/APLNR to promote the HCC development, but also it activates different signal pathways or plays anti-apoptotic and anti-inflammatory functions by promoting tumor angiogenesis (<xref ref-type="bibr" rid="ref-7">Cabiati <italic>et al</italic>., 2021</xref>; <xref ref-type="bibr" rid="ref-50">Wang <italic>et al</italic>., 2020b</xref>). Many factors can affect the development of HCC. Immature and unstable tumor vasculature is associated with abnormal tumor microenvironment, which is liable to pose drug resistance during the anti-cancer treatment. The new peptide apelin and its receptor can enhance immune efficacy by inducing the morphological and functional maturation of tumor blood vessels (<xref ref-type="bibr" rid="ref-25">Kidoya <italic>et al</italic>., 2012</xref>). APLN/APLNR will be up-regulated during tumor angiogenesis. And APLN stimulates the proliferation, migration and invasion of colon adenocarcinomas (<xref ref-type="bibr" rid="ref-40">Picault <italic>et al</italic>., 2014</xref>; <xref ref-type="bibr" rid="ref-41">Podgorska <italic>et al</italic>., 2018</xref>). In addition, increased expression of APLN has been observed in muscle-invasive bladder cancer and is associated with poor clinical outcomes (<xref ref-type="bibr" rid="ref-58">Yang <italic>et al</italic>., 2019</xref>). Studies found that epigenetic modification and Expression of APLN can affect the progression of lung cancer (<xref ref-type="bibr" rid="ref-35">Miller <italic>et al</italic>., 2018</xref>). The degree of CpG island DNAm in APLN is related to the infiltration of pneumonia cells. And the DNA methylation sites in important regions can regulate gene function (<xref ref-type="bibr" rid="ref-36">Mishra <italic>et al</italic>., 2015</xref>). APLN can inhibit tumor progression by regulating Tregs immune cells&#x2019; expression and VCAM-1 (<xref ref-type="bibr" rid="ref-1">Amoozgar <italic>et al</italic>., 2019</xref>). We studied the expression changes of APLN in the development of HCC and its ability to predict prognosis. The methylation sites signatures in epigenetics are used to predict the viability of HCC, which is closely related to APLN.</p>
<p>Our team determined the molecular interaction mechanisms and biomarkers of certain diseases through bioinformatics methods (<xref ref-type="bibr" rid="ref-47">Tian <italic>et al</italic>., 2015</xref>). This study is based on the transcriptome, genetic data of the TCGA dataset and the UCSC dataset to study the prognosis of HCC. First, we used GEPIA and TIMER to screen out suitable genes. Then we screened out APLN gene through PubMed. CIBERSORT&#x2019;s deconvolution can estimate the abundance of 22 kinds of immune cells and differential immune cells. Immune cells and checkpoints are used as clinical traits for WGCNA. And the univariate Cox, Lasso Cox were utilized to construct the risk score. The Nomogram was used to identify the prognostic ability of DNAm signature. The flow chart of this research is shown in the <xref ref-type="fig" rid="fig-1">Fig. 1</xref>.</p>
<fig id="fig-1">
<label>Figure 1</label>
<caption>
<title>Workflow chart for prognostic signature. Based on the UCSC DNAm dataset and TCGA RNA-seq datasets, Univariate COX was used for identifying methylation sites. Differential immune cells were screened out through the results of CIBERSORT. Afterwards, the modules with the highest correlation with immune cells and immune checkpoints were screened through WGCN. And LASSO COX was implemented to select robust survival methylation site characteristics. Finally, the prognostic ability of APLN and APLN-related immune methylation sites is determined.</title></caption>
<graphic mimetype="image" mime-subtype="png" xlink:href="BIOCELL_20198-fig-1.png"/>
</fig>
</sec>
<sec id="s2">
<title>Materials and Methods</title>
<sec id="s2_1">
<title>HCC data and preprocess</title>
<p>Gene expression data (N &#x003D; 422) and clinical data (N &#x003D; 377) of HCC were download from the TCGA database. The Illumina Infinium HumanDNAm450 data in the USUC database (<uri xlink:href="http://xena.ucsc.edu/">http://xena.ucsc.edu/</uri>) was used for the screening of DNA methylation sites. The Beta value matrix data is composed of genomic Matrix (ROWs: site identifier and COLUMNs: sample). Immune genes were download from the Immport database. We deleted samples with survival time less than or equal to 1 day and DNAm Beta Value missing greater than 70%. GEPIA and ENCORI screened out the genes based on survival and expression data of HCC.</p>
</sec>
<sec id="s2_2">
<title>APLN and its expression and survival</title>
<p>In this study, 365 overlapping genes in the TCGA database and the Immport database were used for subsequent analysis. GEPIA (<uri xlink:href="http://gepia2.cancer-pku.cn/">http://gepia2.cancer-pku.cn/</uri>) and ENCORI (<uri xlink:href="http://starbase.sysu.edu.cn/panGeneSurvivalExp.php">http://starbase.sysu.edu.cn/panGeneSurvivalExp.php</uri>) websites used the &#x201C;limma&#x201D; method to analyze overlapping genes. DEGs between the normal group and the cancer group were retained, and genes with a significant difference in survival in the K-M curve (<italic>P</italic> &#x003C; 0.05) were retained. Then we conducted literature research through PubMed, and deleted genes not related to immunity or HCC.</p>
</sec>
<sec id="s2_3">
<title>Analysis of tumor immune microenvironment</title>
<p>A certain proportion of immune cells in cancer samples were analyzed for immune infiltration. According to the median expression of APLN, tumor samples were divided into high expression group and low expression group. The tumor microenvironment immune cell infiltration was analyzed by CIBERSORT (<uri xlink:href="https://cibersort.stanford.edu/">https://cibersort.stanford.edu/</uri>) that based on the deconvolution of gene expression and linear support vector regression. It evaluates the correlation between cell types&#x2019; abundance and survival rate in 22 immune cell molecular subtypes. Then we screened out the types of immune cells with significant differences.</p>
</sec>
<sec id="s2_4">
<title>Key immune methylation sites</title>
<p>(1) To obtain the methylation sites related to APLN gene, the univariate COX regression model was used. (2) The overall survival (OS) and survival status were jointly-used as dependent variables. And the Univariate COX regression model with the methylation sites were performed again. Then we obtained the methylation sites that are significantly related to prognosis. (3) Venn analysis was implemented to yield the methylation sites related to both the APLN and survival. (4) According to the weighted gene co-expression network analysis, <italic><italic>i.e</italic>.</italic>, WGCNA, the essential modules and the immune-related methylation sites were acquired. On the previous step, we used WGCNA to determine the relationship with 3 immune cells and programmed cell death ligand 1 (PD-1), PD-L1, cell Toxic T lymphocyte-associated protein 4 (CTLA-4), the costimulatory molecule B7-1 immune checkpoint had a significant correlation with the key immune methylation sites. Finally, the highest positive/negative correlation module was selected, deemed the most relevant module for immunity.</p>
</sec>
<sec id="s2_5">
<title>Methylation sites signature and risk score</title>
<p>We used LAASO COX to analyze the key immune methylation sites. Then we obtained the signature of the methylation site and the LASSO risk coefficient. Kaplan-Meier (K-M) curve and ROC curve verify the accuracy and predictive power of the risk scoring model. 1, 3, and 5 years of AUC value was judged whether the methylation sites signature has diagnostic value. The LASSO COX retains all feature variables through regularization and reduces all parameters in the loss function. Thereby reducing the loss of feature information and preventing data overfitting. As shown in <xref ref-type="disp-formula" rid="eqn-1">formula (1)</xref>:</p>
<p><disp-formula id="eqn-1"><label>(1)</label>
<mml:math id="mml-eqn-1" display="block"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mfrac><mml:mn>1</mml:mn><mml:mrow><mml:mn>2</mml:mn><mml:mi>m</mml:mi></mml:mrow></mml:mfrac></mml:mrow><mml:mrow><mml:mo>[</mml:mo><mml:mrow><mml:munderover><mml:mrow><mml:mo movablelimits="false">&#x2211;</mml:mo></mml:mrow><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>m</mml:mi></mml:munderover><mml:mo>&#x2061;</mml:mo><mml:mi>g</mml:mi><mml:mi>&#x03B8;</mml:mi><mml:mrow><mml:msup><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mrow><mml:msup><mml:mi>A</mml:mi><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mi>i</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:msup></mml:mrow><mml:mspace width="thickmathspace" /><mml:mo>&#x2212;</mml:mo><mml:mrow><mml:msup><mml:mi>B</mml:mi><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mi>i</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:msup></mml:mrow></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mn>2</mml:mn></mml:msup></mml:mrow><mml:mo>+</mml:mo><mml:mi>&#x03B3;</mml:mi><mml:munderover><mml:mrow><mml:mo movablelimits="false">&#x2211;</mml:mo></mml:mrow><mml:mrow><mml:mi>j</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>K</mml:mi></mml:munderover><mml:mo>&#x2061;</mml:mo><mml:mrow><mml:mo>|</mml:mo><mml:mrow><mml:mrow><mml:msub><mml:mi>W</mml:mi><mml:mi>j</mml:mi></mml:msub></mml:mrow></mml:mrow><mml:mo>|</mml:mo></mml:mrow></mml:mrow><mml:mo>]</mml:mo></mml:mrow></mml:mstyle></mml:math>
</disp-formula></p>
<p>Among them is the L1 regularization term; m is the number of samples; k is the number of parameters; &#x03B3; is the target of the balanced fitting training and the regularization parameter that keeps the parameter value small.</p>
</sec>
<sec id="s2_6">
<title>Prognostic value of APLN and risk score</title>
<p>In the univariate regression analysis, &#x201C;forestplot&#x201D; R package analyzed the impact of APLN and risk score on survival. The nomogram analyzed the prognosis of APLN and methylation site signatures. The 1, 3, and 5-year predicted survival status results are compared with the actual 1, 3, and 5-year survival status to determine the prognostic value of APLN and risk score.</p>
</sec>
<sec id="s2_7">
<title>Statistical analysis</title>
<p>All data statistical processing uses R version 3.6.1 software. Kaplan-Meier curves were generated uses the &#x201C;survival&#x201D; R software package. The R package &#x201C;timeROC&#x201D; performs the ROC analysis to assess the predictive performance of APLN gene and the DNA methylation sites signature. The R package &#x201C;glmnet&#x201D; implements the Lasso analysis that performs 10-fold cross-validation to obtain the best <italic>Lambda value (minimum Lambda value)</italic>. The ward.D algorithm obtains the relationship between 22 immune cells. For all calculated statistical <italic>P</italic> values, it is statistically significant to set <italic>P</italic> &#x003C; 0.05.</p>
</sec>
</sec>
<sec id="s3">
<title>Results</title>
<sec id="s3_1">
<title>Identify the APLN gene</title>
<p>The screening process of APLN gene is shown in the <xref ref-type="fig" rid="fig-2">Fig. 2</xref>. TCGA database and Immport database had 365 overlapping genes. The expression of 9 genes in HCC had significant impact on survival. We Deleted genes unrelated to immunity and genes unrelated to HCC.</p>
<fig id="fig-2">
<label>Figure 2</label>
<caption>
<title>APLN gene screening process. The 365 overlapping genes in the TCGA database and the Immport database are analyzed in the ENCORI and GEPIA2 databases. There are 9 genes with significant differences in gene expression and survival. The above genes were analyzed by TIMER and pubmed. Fially, APLN gene was screened.</title></caption>
<graphic mimetype="image" mime-subtype="png" xlink:href="BIOCELL_20198-fig-2.png"/>
</fig>
</sec>
<sec id="s3_2">
<title>The expression of APLN in HCC is related to clinical features and prognosis</title>
<p>The expression of APLN was significantly up-regulated in 371 tumor samples (<xref ref-type="fig" rid="fig-3">Fig. 3A</xref>; <italic>P</italic> &#x003C; 0.05). APLN tends to increase with the extent of the primary tumor and the grade of cancer tissue (<xref ref-type="fig" rid="fig-3">Figs. 3B</xref> and <xref ref-type="fig" rid="fig-3">3C</xref>, <italic>P</italic> &#x003C; 0.05). The Kaplan-Meier curve in high expression group shown a lower survival rate than low expression one (<xref ref-type="fig" rid="fig-3">Fig. 3D</xref>). And the effective area under the ROC curve (AUC1 &#x003D; 0.64, AUC3 &#x003D; 0.61, AUC5 &#x003D; 0.55) shows that APLN predict patient survival greatly (<xref ref-type="fig" rid="fig-3">Fig. 3E</xref>). The Univariate Cox shown that 66365 DNA methylation sites relate to the expression of APLN and 46208 DNA methylation sites related to survival. A total of 7,229 important DNA methylation sites overlapped in the above two results (<xref ref-type="fig" rid="fig-3">Fig. 3F</xref>).</p>
<fig id="fig-3">
<label>Figure 3</label>
<caption>
<title>The expression of APLN in HCC patients and its relationship with clinical and prognosis. (A) Based on the transcription level of APLN in tumor and normal tissues in the TCGA-LIHC data set (371 tumor samples and 50 normal samples); (B) Different disease stages in TCGA; (C) The expression of APLN in the range of the primary tumor; (D) The impact of APLN gene expression on survival in TCGA; (E) ROC analysis of OS prediction for 1, 3, and 5 years. OS, overall survival; (F) Overlapping methylation sites in TCGA related to survival and APLN expression.</title></caption>
<graphic mimetype="image" mime-subtype="png" xlink:href="BIOCELL_20198-fig-3.png"/>
</fig>
</sec>
<sec id="s3_3">
<title>The relationship between APLN and infiltrating immune cells</title>
<p>The median expression of APLN divides the samples into high expression group and low expression one. Immune infiltration in the immune microenvironment describes the pattern of immune cells. The proportion of tumor immune cells is significantly different between the high expression and low expression. The highest proportions are T cell CD4 memory resting (23.37%), Macrophages M2 (18.57%), and Macrophages M0 (11.75%) (<xref ref-type="fig" rid="fig-4">Fig. 4A</xref>). APLN affects expression of CD4 T cell memory resting (<italic>P</italic> &#x003C; 0.01), T cell follicular helper (<italic>P</italic> &#x003D; 0.001), Tregs (<italic>P</italic> &#x003D; 0.002). Three tumor immune cells have a significant impact (<xref ref-type="fig" rid="fig-4">Fig. 4D</xref>). The relative content of different tumor immune cells in the sample is different (<xref ref-type="fig" rid="fig-4">Fig. 4B</xref>). Spearman method analysis of 22 tumor immune cells reveal the correlation between 22 tumor immune cells (<xref ref-type="fig" rid="fig-4">Fig. 4C</xref>).</p>
<fig id="fig-4">
<label>Figure 4</label>
<caption>
<title>Tumor Infiltrating Immune Cell Analysis by CIBERSORT. (A) Infiltration ratio of 22 immune cells in tumor tissue; (B) Infiltration ratio of 22 immune cells in each tumor sample; (C) Correlation analysis for 22 immune cells; (D) Different immune cells based on APLN expression.</title></caption>
<graphic mimetype="image" mime-subtype="png" xlink:href="BIOCELL_20198-fig-4.png"/>
</fig>
</sec>
<sec id="s3_4">
<title>Key methylation sites associated with immune infiltrating cells</title>
<p>According to univariate COX regression, 19754 methylation sites related to APLN and 56,106 methylation sites related to survival were obtained. The WGCNA analyzed overlapping 6797 DNA methylation sites in 365 samples. HCC is closely related to inflammation, immune cells and immune checkpoints may have important therapeutic value. PD-L1 is the main checkpoint in the tumor immune microenvironment (<xref ref-type="bibr" rid="ref-18">Han <italic>et al</italic>., 2020</xref>). And the PD-1/PD-L1 axis is responsible for cancer immune escape and has a huge impact on cancer treatment (<xref ref-type="bibr" rid="ref-14">Gao <italic>et al</italic>., 2009</xref>). When the threshold (power) is 26, it is closer to the non-network scale distribution (<xref ref-type="fig" rid="fig-5">Figs. 5A</xref> and <xref ref-type="fig" rid="fig-5">5B</xref>). There are 7 highly correlated modules, of which turquoise and brown modules include 106 and 27 important DNA methylation sites (<xref ref-type="fig" rid="fig-5">Fig. 5C</xref>).</p>
<fig id="fig-5">
<label>Figure 5</label>
<caption>
<title>Weighted gene co-expression network analysis of methylation sites (WGCNA). (A) Fitting index &#x03B2; of the law of scale-free network; (B) Module clustering and module-to-module correlation matrix; (C) Correlation analysis between modules and methylation sites, among which turquoise modules and brown modules are most related to immune infiltration.</title></caption>
<graphic mimetype="image" mime-subtype="png" xlink:href="BIOCELL_20198-fig-5.png"/>
</fig>
</sec>
<sec id="s3_5">
<title>Construction and verification of risk score</title>
<p>LASSO COX regression analysis of the above 133 methylation sites finally identified 10 important methylation site signatures (cg02316066, cg06194738, cg07311615, cg07570723, cg15629460, cg16987524, cg18437792, cg21860560, cg22580629). (<xref ref-type="fig" rid="fig-6">Figs. 6A</xref> and <xref ref-type="fig" rid="fig-6">6B</xref>). And the best LASSO coefficient (<xref ref-type="table" rid="table-1">Table 1</xref>). The score is determined based on the signature of 10 methylation sites, risk score &#x003D; cg02316066 &#x00D7; (&#x2013;2.19) &#x002B; cg06194738 &#x00D7; 0.07 &#x002B; cg07311615 &#x00D7; 0.24 &#x002B; cg07570723 &#x00D7; (0.99) &#x002B; cg15629460 &#x00D7; 1.99 &#x002B; cg16987524 &#x00D7; 0.10 &#x002B; cg18437792 &#x00D7; (0.04) &#x002B; cg21860560 &#x00D7; 0.98 &#x002B; cg22580629 &#x00D7; (&#x2212;0.09). The results of the K-M curve show that the proportion of high risk in the cancer group is high (<italic>P</italic> &#x003D; 0.00014 (<xref ref-type="fig" rid="fig-6">Fig. 6C</xref>)) and good predictive effect (AUC1 &#x003D; 0.61, AUC3 &#x003D; 0.64, AUC5 &#x003D; 0.63) (<xref ref-type="fig" rid="fig-6">Fig. 6D</xref>). The 365 samples were randomly divided into a verification set and a training set at a ratio of 1:2. The validation set results are consistent with those of 365 samples, and the risk score can predict the prognosis great (<xref ref-type="fig" rid="fig-7">Figs. 7A</xref> and <xref ref-type="fig" rid="fig-7">7B</xref>).</p>
<fig id="fig-6">
<label>Figure 6</label>
<caption>
<title>LASSO model and verification. (A) LASSO coefficient distribution map of 133 methylation sites; (B) Penalty graph of 133 prognostic methylation sites of the LASSO model, with error bars representing standard errors; (C) Kaplan-Meier curve of OS survival status between the high-risk score group and the low-risk score group; (D) Predict the time-dependent ROC curve analysis of OS for 1, 3, and 5 years based on the risk score.</title></caption>
<graphic mimetype="image" mime-subtype="png" xlink:href="BIOCELL_20198-fig-6.png"/>
</fig>
<table-wrap id="table-1"><label>Table 1</label>
<caption>
<title>Lasso coefficients of 10 methylation sites signatures</title></caption>
<table><colgroup>
<col/>
<col/>
<col/>
<col/>
</colgroup>
<thead>
<tr>
<th></th>
<th>LASSO</th>
<th>HR (95% CI for HR)</th>
<th><italic>P</italic></th>
</tr>
</thead>
<tbody>
<tr>
<td>cg02316066</td>
<td>&#x2013;2.19263556</td>
<td>0.2187911 (0.075433&#x2013;0.63459)</td>
<td>0.005157998</td>
</tr>
<tr>
<td>cg06194738</td>
<td>0.07161149</td>
<td>0.1808663 (0.051038&#x2013;0.64095)</td>
<td>0.008072275</td>
</tr>
<tr>
<td>cg07311615</td>
<td>0.24275158</td>
<td>0.1160625 (0.036823&#x2013;0.36582)</td>
<td>0.000236175</td>
</tr>
<tr>
<td>cg07570723</td>
<td>&#x2013;0.98831233</td>
<td>15.75428 (3.2714&#x2013;75.869)</td>
<td>0.000586481</td>
</tr>
<tr>
<td>cg15629460</td>
<td>1.99862009</td>
<td>0.1446901 (0.051023&#x2013;0.41031)</td>
<td>0.00027788</td>
</tr>
<tr>
<td>cg16987524</td>
<td>0.09831357</td>
<td>0.1714786 (0.059379&#x2013;0.49521)</td>
<td>0.001118894</td>
</tr>
<tr>
<td>cg18437792</td>
<td>&#x2013;0.04105067</td>
<td>5.616418 (2.2943&#x2013;13.749)</td>
<td>0.000158072</td>
</tr>
<tr>
<td>cg21860560</td>
<td>0.98428153</td>
<td>0.1179268 (0.038934&#x2013;0.35719)</td>
<td>0.000156354</td>
</tr>
<tr>
<td>cg22580629</td>
<td>&#x2013;0.09059213</td>
<td>20.07344 (2.9252&#x2013;137.75)</td>
<td>0.002271316</td>
</tr>
<tr>
<td>cg23240927</td>
<td>&#x2013;0.77036311</td>
<td>2.815473 (1.2995&#x2013;6.0998)</td>
<td>0.008685544</td>
</tr>
</tbody>
</table>
</table-wrap>
<fig id="fig-7">
<label>Figure 7</label>
<caption>
<title>Validation set. (A) Kaplan-Meier curve of OS survival status between the high-risk score group and the low-risk score group; (B) The time-dependent ROC curve analysis of OS for 1, 3, and 5 years based on the risk score.</title></caption>
<graphic mimetype="image" mime-subtype="png" xlink:href="BIOCELL_20198-fig-7.png"/>
</fig>
</sec>
<sec id="s3_6">
<title>DNA methylation sites signature and the prognostic value of APLN</title>
<p>Univariate analysis was used to screen out the variables related to patient survival. The results showed that APLN expression, risk score, and tumor stage T all had significant effects on patient survival. (<xref ref-type="fig" rid="fig-8">Figs. 8A</xref> and <xref ref-type="fig" rid="fig-8">8B</xref>). Factors with significant differences are used as Nomogram predictors. The results showed that the survival prediction is in good agreement with the actual observations (<xref ref-type="fig" rid="fig-8">Fig. 8C</xref>).</p>
<fig id="fig-8">
<label>Figure 8</label>
<caption>
<title>Prognostic analysis of APLN and risk score. (A) One-way COX prognostic regression model based on TCGA and UCSCD data sets; (B) APLN, risk score, stage, T stage combined with nomogram survival prediction; (C) The prediction and actual 1, 3, 5-year survival rate.</title></caption>
<graphic mimetype="image" mime-subtype="png" xlink:href="BIOCELL_20198-fig-8.png"/>
</fig>
</sec>
</sec>
<sec id="s4">
<title>Discussion</title>
<p>Conventional treatment for HCC is highly invasive. And early prediction and personalized therapy of targeted immune checkpoints have research significance (<xref ref-type="bibr" rid="ref-61">Yin <italic>et al</italic>., 2019</xref>; <xref ref-type="bibr" rid="ref-63">Wang <italic>et al.</italic>, 2021</xref>). APLN and DNAm are abnormally expressed in a variety of cancers. But the role of APLN in the immune microenvironment development of HCC is still unknown. APLN is up-regulated in HCC and HCC38/KMUH cells and may be used as a therapeutic target (<xref ref-type="bibr" rid="ref-30">Lin <italic>et al</italic>., 2012</xref>; <xref ref-type="bibr" rid="ref-9">Chen <italic>et al</italic>., 2019</xref>). APLN is a carcinogen that is highly expressed and its expression trend is increasing with HCC development. APLN, as a transcriptional target of the Wnt/&#x03B2;-catenin pathway, promotes HCC by activating PI3K/Akt signaling. The pharmacological targeting of APLN strongly inhibits the proliferation of HCC cells and tumor growth, which means that APLN may be a potential drug target for HCC. The gene has significant differences in the expression and clinical characteristics between the tumor and normal tissues. It has the potential prognostic value. The Cox regression model predicts the risk prediction characteristics significantly related to OS. Finally, the prognostic value of the risk prediction was verified by the nomogram.</p>
<p>The study determined that the proportion of total T cells in HCC cells is greater than in healthy tissues. And T cell subsets mainly include T cell CD4 memory resting, follicular helper T cells, etc., which impact the prognosis of HCC (<xref ref-type="bibr" rid="ref-23">Jia <italic>et al</italic>., 2015a</xref>; <xref ref-type="bibr" rid="ref-44">Rohr-Udilova <italic>et al</italic>., 2018</xref>; <xref ref-type="bibr" rid="ref-15">Garnelo <italic>et al</italic>., 2017</xref>). APLN affects three types of immune cells, including T cell CD4 memory resting, follicular helper T cells, and Tregs, highlighting the poor clinical correlation between T cell-mediated immunity and tumors (<xref ref-type="bibr" rid="ref-28">Li <italic>et al</italic>., 2021</xref>). Both PD-1 and CTLA-4 are related to some subsets of T cells, and mainly affect the development of tumors through PD-1/PD-L1 acting on T cells (<xref ref-type="bibr" rid="ref-26">Kim and Chen, 2016</xref>). PD-1 and PD-L1 interaction can resulting in inactivation of the immune response (<xref ref-type="bibr" rid="ref-64">Poureau and Metges, 2021</xref>). PD-1 is the main checkpoint in TME. Follicular helper T cells can inhibit the expression of Treg cells by affecting the expression of PD-1. And CTLA-4 can also enhance the immunosuppressive activity of Treg (a key mediator of CTLA-4) by regulating follicular helper T cells (<xref ref-type="bibr" rid="ref-24">Jia <italic>et al</italic>., 2015b</xref>; <xref ref-type="bibr" rid="ref-19">Hervouet, 1970</xref>; <xref ref-type="bibr" rid="ref-60">Yang <italic>et al</italic>., 2014</xref>; <xref ref-type="bibr" rid="ref-48">Topalian <italic>et al</italic>., 2016</xref>). The expression of APLN and specific immune cells play an essential role in the tumor progression of HCC (<xref ref-type="bibr" rid="ref-49">Wang <italic>et al</italic>., 2020a</xref>). APLN can regulate or induce the morphological and functional maturation of tumor blood vessels. And the recruitment of dendritic immune cells helps to enhance the effect of immunotherapy (<xref ref-type="bibr" rid="ref-25">Kidoya <italic>et al</italic>., 2012</xref>). Closely related to the HCC prognosis, the immune microenvironment is complex and usually heterogeneous with several genomic alterations, therefore making meaningful the integrated investigation of immune microenvironment with the DNA methylation sites of APLN in studies of HCC prognosis.</p>
<p>Not only does tumor-related macrophages promote thrombosis and endocytosis, angiogenesis, invasion and metastasis, but also it inhibits anti-tumor immune responses (<xref ref-type="bibr" rid="ref-29">Lin <italic>et al</italic>., 2019</xref>). Tumor-associated macrophages are mainly polarized into Macrophages M1 and Macrophages M2. The former plays an anti-tumor effect, while the latter has a tumor-promoting effect. Macrophages M2 mainly induces anti-inflammatory responses by producing IL-10 and (TGF)-&#x03B2;, meanwhile participating in the polarization of Th2 responses to promote tumor growth (<xref ref-type="bibr" rid="ref-53">Wildes <italic>et al</italic>., 2020</xref>; <xref ref-type="bibr" rid="ref-5">Biswas and Mantovani, 2010</xref>; <xref ref-type="bibr" rid="ref-54">Wolf-Dennen <italic>et al</italic>., 2020</xref>). Taking a higher percentage in HBV, non-polarized Macrophages M0 also affect the HCC prognosis (<xref ref-type="bibr" rid="ref-11">Ding <italic>et al</italic>., 2021</xref>; <xref ref-type="bibr" rid="ref-20">Huo <italic>et al</italic>., 2020</xref>). APLNs induce tumor vascular maturation and promote the infiltration of natural killer T cells into the central region of the tumor. This process enhances the efficacy of cancer dendritic cell-based immunotherapies (<xref ref-type="bibr" rid="ref-34">Mastrella <italic>et al</italic>., 2019</xref>). APLN inhibits and reduces neutrophil recruitment, thereby reducing the inflammatory and fibrotic response of pancreatitis. It also inhibits macrophage infiltration and monocytes, thereby enhancing the stable phenotype of atherosclerotic plaques (<xref ref-type="bibr" rid="ref-22">Ioannidis <italic>et al</italic>., 2010</xref>).</p>
<p>The signatures that DNA methylation sites analyzed by LASSO COX prevent data from overfitting. Studies found that the combination of selected central genes and DNAm conditions has an advantage in predicting the survival of HNSCC (<xref ref-type="bibr" rid="ref-37">Mou <italic>et al</italic>., 2020</xref>; <xref ref-type="bibr" rid="ref-8">Cao <italic>et al</italic>., 2020</xref>). The human m6A near the mRNA stop codon and the 3&#x2019; untranslated region will affect the transcription and function of genes through the promoter DNAm (<xref ref-type="bibr" rid="ref-39">Ondo <italic>et al</italic>., 2021</xref>). Usually, DNAm inhibits gene expression. APLN and the probe cg05688478 can affect gene expression in human pancreatic islets (<xref ref-type="bibr" rid="ref-17">Hall <italic>et al</italic>., 2014</xref>). The interaction of genome (gene expression) and epigenome (DNAm level) to control Apelin endothelium is one of the most critical ways for non-triple-negative breast cancer (<xref ref-type="bibr" rid="ref-55">Wu <italic>et al</italic>., 2020</xref>). DNA methylation silences the APLN expression, leading to increased insulin secretion in women (<xref ref-type="bibr" rid="ref-17">Hall <italic>et al</italic>., 2014</xref>). In APLN, rs3761581 G and rs2235312 T are relative to the degree of CpG island. Low levels of apelin-13 will cause greater methylation of CpG islands in the 5&#x2019;UTR, which contributes to the pathophysiology of HA lung water. Abnormal methylation may prevent apelin from binding to hypoxia response elements, thereby inhibiting APLN transcription (<xref ref-type="bibr" rid="ref-36">Mishra <italic>et al</italic>., 2015</xref>). In downstream of DNA damage, the increased methylation of the APLN promoter may lead to reductions in protective signaling of the apeliner energy system. Then it lead to the pulmonary edema observed after exposure to oxidative air pollution (<xref ref-type="bibr" rid="ref-35">Miller <italic>et al</italic>., 2018</xref>).</p>
<p>The interaction between the genome and the epigenome will also change the evolution and control the development of different cancers. Epigenetic controlled immunotherapy has potential effects such as restoring anti-tumor signals (<xref ref-type="bibr" rid="ref-16">Gomez <italic>et al</italic>., 2020</xref>). Many sites in the DNAm region and epigenetic changes play an essential role in the early stage of liver cancer (<xref ref-type="bibr" rid="ref-45">Seal <italic>et al</italic>., 2020</xref>). The DNAm mechanism would regulate the immune cell response of cancer. Different DNAm patterns will also affect the characteristics of immune infiltration (<xref ref-type="bibr" rid="ref-55">Wu <italic>et al</italic>., 2020</xref>; <xref ref-type="bibr" rid="ref-12">Du <italic>et al</italic>., 2021</xref>). Epigenetics and gene expression influence each other (<xref ref-type="bibr" rid="ref-36">Mishra <italic>et al</italic>., 2015</xref>; <xref ref-type="bibr" rid="ref-51">Wang <italic>et al</italic>., 2020c</xref>). Studies have found that the CpG island of APLN has a more significant impact on lung tissue. The combined study of APLN and epigenetic DNA methylation sites are significantly related to survival. Research using epigenetics, gene transcriptome, and immune data, predicting prognostic markers of HCC has great potential.</p>
<p>The study still has limitations. The samples we studied are entirely retrospective. The data bias may affect survival and DNAm signatures. Although we determined the selected DNA methylation sites and APLN as predictive features, more experimental studies are still needed.</p>
</sec>
<sec id="s5">
<title>Conclusions</title>
<p>In summary, our research combines transcription, epigenetics, and immune data to predict HCC prognosis. The novel biomarkers immune-related APLN may be reliable prognostic markers for HCC.</p>
</sec>
</body>
<back>
<glossary content-type="abbreviations" id="glossary-1">
<title>Abbreviations</title>
<def-list>
<def-item>
<term>HCC:</term>
<def>
<p>hepatocellular carcinoma</p>
</def>
</def-item>
<def-item>
<term>K-M:</term>
<def>
<p>Kaplan&#x2013;Meier</p>
</def>
</def-item>
<def-item>
<term>LASSO:</term>
<def>
<p>least absolute shrinkage and selection operator</p>
</def>
</def-item>
<def-item>
<term>TCGA:</term>
<def>
<p>the cancer genome atlas</p>
</def>
</def-item>
<def-item>
<term>WGCNA:</term>
<def>
<p>weighted gene co-expression network analysis</p>
</def>
</def-item>
<def-item>
<term>DNAm:</term>
<def>
<p>DNA methylation</p>
</def>
</def-item>
<def-item>
<term>UCSC:</term>
<def>
<p>University of California, Santa Cruz</p>
</def>
</def-item>
</def-list>
</glossary>
<fn-group>
<fn fn-type="other">
<p><bold>Author Contribution:</bold> The authors confirm contribution to the paper as follows: Feifei Tian and Huan Hu wrote the manuscript and performed the statistically analyses; Di Wang and Huan Ding took part in data collection. Qingjia Chi and Huaping Liang prepared some figures and contributed to revise the manuscript; Wenli Zeng designed the work. All the authors read and approved the final manuscript.</p>
</fn>
<fn fn-type="other">
<p><bold>Availability of Data and Materials:</bold> The datasets generated during the current study are available from the corresponding author on reasonable request.</p>
</fn>
<fn fn-type="other">
<p><bold>Funding Statement:</bold> This work was supported by the Fund of Biosecurity Specialized Project of PLA (No. 19SWAQ18).</p>
</fn>
<fn fn-type="conflict">
<p><bold>Conflicts of Interest:</bold> The authors declare that they have no conflicts of interest to report regarding the present study.</p>
</fn>
</fn-group>
<ref-list content-type="authoryear">
<title>References</title>
<ref id="ref-1"><label>Amoozgar <italic>et al</italic>. (2019)</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Amoozgar</surname> <given-names>Z</given-names></string-name>, <string-name><surname>Jain</surname> <given-names>RK</given-names></string-name>, <string-name><surname>Duda</surname> <given-names>DG</given-names></string-name></person-group> (<year>2019</year>). <article-title>Role of apelin in glioblastoma vascularization and invasion after anti-VEGF therapy: What is the impact on the immune system?</article-title> <source>Cancer Research</source> <volume>79</volume>: <fpage>2104</fpage>&#x2013;<lpage>2106</lpage>. DOI <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-19-0749</pub-id>.</mixed-citation></ref>
<ref id="ref-2"><label>Ashokan et al. (2021)</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ashokan</surname> <given-names>A</given-names></string-name>, <string-name><surname>Harisankar</surname> <given-names>HS</given-names></string-name>, <string-name><surname>Kameswaran</surname> <given-names>M</given-names></string-name>, <string-name><surname>Aradhyam</surname> <given-names>GK</given-names></string-name></person-group> (<year>2021</year>). <article-title>Critical APJ receptor residues in extracellular domains that influence effector selectivity</article-title>. <source>FEBS Journal</source> <volume>288</volume>: <fpage>6543</fpage>&#x2013;<lpage>6562</lpage>. DOI <pub-id pub-id-type="doi">10.1111/febs.16048</pub-id>.</mixed-citation></ref>
<ref id="ref-3"><label>Bai <italic>et al</italic>. (2020)</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Bai</surname> <given-names>S</given-names></string-name>, <string-name><surname>Wu</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Yan</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Shao</surname> <given-names>S</given-names></string-name>, <string-name><surname>Zhang</surname> <given-names>J</given-names></string-name> <etal>et al.</etal></person-group> (<year>2020</year>). <article-title>Construct a circRNA/miRNA/mRNA regulatory network to explore potential pathogenesis and therapy options of clear cell renal cell carcinoma</article-title>. <source>Scientific Reports</source> <volume>10</volume>: <fpage>13659</fpage>. DOI <pub-id pub-id-type="doi">10.1038/s41598-020-70484-2</pub-id>.</mixed-citation></ref>
<ref id="ref-4"><label>Baylin and Jones (2011)</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Baylin</surname> <given-names>SB</given-names></string-name>, <string-name><surname>Jones</surname> <given-names>PA</given-names></string-name></person-group> (<year>2011</year>). <article-title>A decade of exploring the cancer epigenome-biological and translational implications</article-title>. <source>Nature Reviews Cancer</source> <volume>11</volume>: <fpage>726</fpage>&#x2013;<lpage>734</lpage>. DOI <pub-id pub-id-type="doi">10.1038/nrc3130</pub-id>.</mixed-citation></ref>
<ref id="ref-5"><label>Biswas and Mantovani (2010)</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Biswas</surname> <given-names>SK</given-names></string-name>, <string-name><surname>Mantovani</surname> <given-names>A</given-names></string-name></person-group> (<year>2010</year>). <article-title>Macrophage plasticity and interaction with lymphocyte subsets: Cancer as a paradigm</article-title>. <source>Nature Immunology</source> <volume>11</volume>: <fpage>889</fpage>&#x2013;<lpage>896</lpage>. DOI <pub-id pub-id-type="doi">10.1038/ni.1937</pub-id>.</mixed-citation></ref>
<ref id="ref-6"><label>Brown <italic>et al</italic>. (2019)</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Brown</surname> <given-names>ZJ</given-names></string-name>, <string-name><surname>Greten</surname> <given-names>TF</given-names></string-name>, <string-name><surname>Heinrich</surname> <given-names>B</given-names></string-name></person-group> (<year>2019</year>). <article-title>Adjuvant treatment of hepatocellular carcinoma: Prospect of immunotherapy</article-title>. <source>Hepatology</source> <volume>70</volume>: <fpage>1437</fpage>&#x2013;<lpage>1442</lpage>. DOI <pub-id pub-id-type="doi">10.1002/hep.30633</pub-id>.</mixed-citation></ref>
<ref id="ref-7"><label>Cabiati <italic>et al</italic>. (2021)</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Cabiati</surname> <given-names>M</given-names></string-name>, <string-name><surname>Gaggini</surname> <given-names>M</given-names></string-name>, <string-name><surname>de Simone</surname> <given-names>P</given-names></string-name>, <string-name><surname>Del</surname> <given-names>RS</given-names></string-name></person-group> (<year>2021</year>). <article-title>Evaluation of Apelin/APJ system expression in hepatocellular carcinoma as a function of clinical severity</article-title>. <source>Clinical and Experimental Medicine</source> <volume>21</volume>: <fpage>269</fpage>&#x2013;<lpage>275</lpage>. DOI <pub-id pub-id-type="doi">10.1007/s10238-020-00672-x</pub-id>.</mixed-citation></ref>
<ref id="ref-8"><label>Cao et al. (2020)</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Cao</surname> <given-names>Z</given-names></string-name>, <string-name><surname>Ao</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Guo</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Zhou</surname> <given-names>S</given-names></string-name></person-group> (<year>2020</year>). <article-title>Comprehensive analysis of mRNA expression profiles in head and neck cancer by using robust rank aggregation and weighted gene coexpression network analysis</article-title>. <source>BioMed Research International</source> <volume>2020</volume>: <fpage>4908427</fpage>. DOI <pub-id pub-id-type="doi">10.1155/2020/4908427</pub-id>.</mixed-citation></ref>
<ref id="ref-9"><label>Chen et al. (2019)</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Chen</surname> <given-names>H</given-names></string-name>, <string-name><surname>Wong</surname> <given-names>CC</given-names></string-name>, <string-name><surname>Liu</surname> <given-names>D</given-names></string-name>, <string-name><surname>Go</surname> <given-names>M</given-names></string-name>, <string-name><surname>Wu</surname> <given-names>B</given-names></string-name> <etal>et al.</etal></person-group> (<year>2019</year>). <article-title>APLN promotes hepatocellular carcinoma through activating PI3K/Akt pathway and is a druggable target</article-title>. <source>Theranostics</source> <volume>9</volume>: <fpage>5246</fpage>&#x2013;<lpage>5260</lpage>. DOI <pub-id pub-id-type="doi">10.7150/thno.34713</pub-id>.</mixed-citation></ref>
<ref id="ref-10"><label>Chen <italic>et al</italic>. (2021)</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Chen</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Xu</surname> <given-names>T</given-names></string-name>, <string-name><surname>Xie</surname> <given-names>F</given-names></string-name>, <string-name><surname>Wang</surname> <given-names>L</given-names></string-name>, <string-name><surname>Liang</surname> <given-names>Z</given-names></string-name> <etal>et al.</etal></person-group> (<year>2021</year>). <article-title>Evaluating the biological functions of the prognostic genes identified by the Pathology Atlas in bladder cancer</article-title>. <source>Oncology Reports</source> <volume>45</volume>: <fpage>191</fpage>&#x2013;<lpage>201</lpage>. DOI <pub-id pub-id-type="doi">10.3892/or.2020.7853</pub-id>.</mixed-citation></ref>
<ref id="ref-11"><label>Ding <italic>et al</italic>. (2021)</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ding</surname> <given-names>Z</given-names></string-name>, <string-name><surname>Dong</surname> <given-names>Z</given-names></string-name>, <string-name><surname>Chen</surname> <given-names>Z</given-names></string-name>, <string-name><surname>Hong</surname> <given-names>J</given-names></string-name>, <string-name><surname>Yan</surname> <given-names>L</given-names></string-name> <etal>et al.</etal></person-group> (<year>2021</year>). <article-title>Viral status and efficacy of immunotherapy in hepatocellular carcinoma: A systematic review with meta-analysis</article-title>. <source>Frontiers in Immunology</source> <volume>12</volume>: <fpage>733530</fpage>. DOI <pub-id pub-id-type="doi">10.3389/fimmu.2021.733530</pub-id>.</mixed-citation></ref>
<ref id="ref-12"><label>Du et al. (2021)</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Du</surname> <given-names>J</given-names></string-name>, <string-name><surname>Ji</surname> <given-names>H</given-names></string-name>, <string-name><surname>Ma</surname> <given-names>S</given-names></string-name>, <string-name><surname>Jin</surname> <given-names>J</given-names></string-name>, <string-name><surname>Mi</surname> <given-names>S</given-names></string-name> <etal>et al.</etal></person-group> (<year>2021</year>). <article-title>m6A regulator-mediated methylation modification patterns and characteristics of immunity and stemness in low-grade glioma</article-title>. <source>Briefings in Bioinformatics</source> <volume>22</volume>: <fpage>bbab013</fpage>. DOI <pub-id pub-id-type="doi">10.1093/bib/bbab013</pub-id>.</mixed-citation></ref>
<ref id="ref-13"><label>Dzobo et al. (2020)</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Dzobo</surname> <given-names>K</given-names></string-name>, <string-name><surname>Senthebane</surname> <given-names>DA</given-names></string-name>, <string-name><surname>Ganz</surname> <given-names>C</given-names></string-name>, <string-name><surname>Thomford</surname> <given-names>NE</given-names></string-name>, <string-name><surname>Wonkam</surname> <given-names>A</given-names></string-name> <etal>et al.</etal></person-group> (<year>2020</year>). <article-title>Advances in therapeutic targeting of cancer stem cells within the tumor microenvironment: An updated review</article-title>. <source>Cells</source> <volume>9</volume>: <fpage>1896</fpage>. DOI <pub-id pub-id-type="doi">10.3390/cells9081896</pub-id>.</mixed-citation></ref>
<ref id="ref-14"><label>Gao <italic>et al</italic>. (2009)</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Gao</surname> <given-names>Q</given-names></string-name>, <string-name><surname>Wang</surname> <given-names>XY</given-names></string-name>, <string-name><surname>Qiu</surname> <given-names>SJ</given-names></string-name>, <string-name><surname>Yamato</surname> <given-names>I</given-names></string-name>, <string-name><surname>Sho</surname> <given-names>M</given-names></string-name> <etal>et al.</etal></person-group> (<year>2009</year>). <article-title>Overexpression of PD-L1 significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma</article-title>. <source>Clinical Cancer Research</source> <volume>15</volume>: <fpage>971</fpage>&#x2013;<lpage>979</lpage>. DOI <pub-id pub-id-type="doi">10.1158/1078-0432.CCR-08-1608</pub-id>.</mixed-citation></ref>
<ref id="ref-15"><label>Garnelo <italic>et al</italic>. (2017)</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Garnelo</surname> <given-names>M</given-names></string-name>, <string-name><surname>Tan</surname> <given-names>A</given-names></string-name>, <string-name><surname>Her</surname> <given-names>Z</given-names></string-name>, <string-name><surname>Yeong</surname> <given-names>J</given-names></string-name>, <string-name><surname>Lim</surname> <given-names>CJ</given-names></string-name> <etal>et al.</etal></person-group> (<year>2017</year>). <article-title>Interaction between tumour-infiltrating B cells and T cells controls the progression of hepatocellular carcinoma</article-title>. <source>Gut</source> <volume>66</volume>: <fpage>342</fpage>&#x2013;<lpage>351</lpage>. DOI <pub-id pub-id-type="doi">10.1136/gutjnl-2015-310814</pub-id>.</mixed-citation></ref>
<ref id="ref-16"><label>Gomez <italic>et al</italic>. (2020)</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Gomez</surname> <given-names>S</given-names></string-name>, <string-name><surname>Tabernacki</surname> <given-names>T</given-names></string-name>, <string-name><surname>Kobyra</surname> <given-names>J</given-names></string-name>, <string-name><surname>Roberts</surname> <given-names>P</given-names></string-name>, <string-name><surname>Chiappinelli</surname> <given-names>KB</given-names></string-name></person-group> (<year>2020</year>). <article-title>Combining epigenetic and immune therapy to overcome cancer resistance</article-title>. <source>Seminars in Cancer Biology</source> <volume>65</volume>: <fpage>99</fpage>&#x2013;<lpage>113</lpage>. DOI <pub-id pub-id-type="doi">10.1016/j.semcancer.2019.12.019</pub-id>.</mixed-citation></ref>
<ref id="ref-17"><label>Hall et al. (2014)</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hall</surname> <given-names>E</given-names></string-name>, <string-name><surname>Volkov</surname> <given-names>P</given-names></string-name>, <string-name><surname>Dayeh</surname> <given-names>T</given-names></string-name>, <string-name><surname>Esguerra</surname> <given-names>JL</given-names></string-name>, <string-name><surname>Salo</surname> <given-names>S</given-names></string-name> <etal>et al.</etal></person-group> (<year>2014</year>). <article-title>Sex differences in the genome-wide DNA methylation pattern and impact on gene expression, microRNA levels and insulin secretion in human pancreatic islets</article-title>. <source>Genome Biology</source> <volume>15</volume>: <fpage>522</fpage>. DOI <pub-id pub-id-type="doi">10.1186/s13059-014-0522-z</pub-id>.</mixed-citation></ref>
<ref id="ref-18"><label>Han et al. (2020)</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Han</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Liu</surname> <given-names>D</given-names></string-name>, <string-name><surname>Li</surname> <given-names>L</given-names></string-name></person-group> (<year>2020</year>). <article-title>PD-1/PD-L1 pathway: Current researches in cancer</article-title>. <source>American Journal of Cancer Research</source> <volume>10</volume>: <fpage>727</fpage>&#x2013;<lpage>742</lpage>.</mixed-citation></ref>
<ref id="ref-19"><label>Hervouet (1970)</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hervouet</surname> <given-names>F</given-names></string-name></person-group> (<year>1970</year>). <article-title>Treatment of blepharospasm by resection of the musculus orbicularis</article-title>. <source>Bulletin des societes d&#x2019;ophtalmologie de France</source> <volume>70</volume>: <fpage>846</fpage>.</mixed-citation></ref>
<ref id="ref-20"><label>Huo <italic>et al</italic>. (2020)</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Huo</surname> <given-names>J</given-names></string-name>, <string-name><surname>Wu</surname> <given-names>L</given-names></string-name>, <string-name><surname>Zang</surname> <given-names>Y</given-names></string-name></person-group> (<year>2020</year>). <article-title>Development and validation of a novel immune-gene pairs prognostic model associated with CTNNB1 alteration in hepatocellular carcinoma</article-title>. <source>Medical Science Monitor</source> <volume>26</volume>: <fpage>e925494</fpage>. DOI <pub-id pub-id-type="doi">10.12659/MSM.925494</pub-id>.</mixed-citation></ref>
<ref id="ref-21"><label>Ibrahim <italic>et al</italic>. (2011)</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ibrahim</surname> <given-names>AE</given-names></string-name>, <string-name><surname>Arends</surname> <given-names>MJ</given-names></string-name>, <string-name><surname>Silva</surname> <given-names>AL</given-names></string-name>, <string-name><surname>Wyllie</surname> <given-names>AH</given-names></string-name>, <string-name><surname>Greger</surname> <given-names>L</given-names></string-name> <etal>et al.</etal></person-group> (<year>2011</year>). <article-title>Sequential DNA methylation changes are associated with DNMT3B overexpression in colorectal neoplastic progression</article-title>. <source>Gut</source> <volume>60</volume>: <fpage>499</fpage>&#x2013;<lpage>508</lpage>. DOI <pub-id pub-id-type="doi">10.1136/gut.2010.223602</pub-id>.</mixed-citation></ref>
<ref id="ref-22"><label>Ioannidis <italic>et al</italic>. (2010)</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ioannidis</surname> <given-names>JP</given-names></string-name>, <string-name><surname>Tatsioni</surname> <given-names>A</given-names></string-name>, <string-name><surname>Karassa</surname> <given-names>FB</given-names></string-name></person-group> (<year>2010</year>). <article-title>A vision for the European journal of clinical investigation: Note from the new editors</article-title>. <source>European Journal of Clinical Investigation</source> <volume>40</volume>: <fpage>1</fpage>&#x2013;<lpage>3</lpage>. DOI <pub-id pub-id-type="doi">10.1111/j.1365-2362.2009.02229.x</pub-id>.</mixed-citation></ref>
<ref id="ref-23"><label>Jia et al. (2015a)</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Jia</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Zeng</surname> <given-names>Z</given-names></string-name>, <string-name><surname>Li</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Li</surname> <given-names>Z</given-names></string-name>, <string-name><surname>Jin</surname> <given-names>L</given-names></string-name> <etal>et al.</etal></person-group> (<year>2015a</year>). <article-title>Impaired function of CD4&#x002B; T follicular helper (Tfh) cells associated with hepatocellular carcinoma progression</article-title>. <source>PLoS One</source> <volume>10</volume>: <fpage>e0117458</fpage>. DOI <pub-id pub-id-type="doi">10.1371/journal.pone.0117458</pub-id>.</mixed-citation></ref>
<ref id="ref-24"><label>Jia et al. (2015b)</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Jia</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Zeng</surname> <given-names>Z</given-names></string-name>, <string-name><surname>Li</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Li</surname> <given-names>Z</given-names></string-name>, <string-name><surname>Jin</surname> <given-names>L</given-names></string-name> <etal>et al.</etal></person-group> (<year>2015b</year>). <article-title>Impaired function of CD4&#x002B; T follicular helper (Tfh) cells associated with hepatocellular carcinoma progression</article-title>. <source>PLoS One</source> <volume>10</volume>: <fpage>e0117458</fpage>. DOI <pub-id pub-id-type="doi">10.1371/journal.pone.0117458</pub-id>.</mixed-citation></ref>
<ref id="ref-25"><label>Kidoya et al. (2012)</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kidoya</surname> <given-names>H</given-names></string-name>, <string-name><surname>Kunii</surname> <given-names>N</given-names></string-name>, <string-name><surname>Naito</surname> <given-names>H</given-names></string-name>, <string-name><surname>Muramatsu</surname> <given-names>F</given-names></string-name>, <string-name><surname>Okamoto</surname> <given-names>Y</given-names></string-name> <etal>et al.</etal></person-group> (<year>2012</year>). <article-title>The apelin/APJ system induces maturation of the tumor vasculature and improves the efficiency of immune therapy</article-title>. <source>Oncogene</source> <volume>31</volume>: <fpage>3254</fpage>&#x2013;<lpage>3264</lpage>. DOI <pub-id pub-id-type="doi">10.1038/onc.2011.489</pub-id>.</mixed-citation></ref>
<ref id="ref-26"><label>Kim and Chen (2016)</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kim</surname> <given-names>JM</given-names></string-name>, <string-name><surname>Chen</surname> <given-names>DS</given-names></string-name></person-group> (<year>2016</year>). <article-title>Immune escape to PD-L1/PD-1 blockade: Seven steps to success (or failure)</article-title>. <source>Annals of Oncology</source> <volume>27</volume>: <fpage>1492</fpage>&#x2013;<lpage>1504</lpage>. DOI <pub-id pub-id-type="doi">10.1093/annonc/mdw217</pub-id>.</mixed-citation></ref>
<ref id="ref-27"><label>Korean Liver Cancer Association (2019)</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><collab>Korean Liver Cancer Association</collab></person-group> (<year>2019</year>). <article-title>National cancer center korea practice guidelines for the management of hepatocellular carcinoma</article-title>. <source>Korean Journal of Radiology</source> <volume>20</volume>: <fpage>1042</fpage>&#x2013;<lpage>1113</lpage>. DOI <pub-id pub-id-type="doi">10.3348/kjr.2019.0140</pub-id>.</mixed-citation></ref>
<ref id="ref-28"><label>Li et al. (2021)</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Li</surname> <given-names>XT</given-names></string-name>, <string-name><surname>Zhang</surname> <given-names>JT</given-names></string-name>, <string-name><surname>Yan</surname> <given-names>HH</given-names></string-name>, <string-name><surname>Su</surname> <given-names>J</given-names></string-name>, <string-name><surname>Cheng</surname> <given-names>ML</given-names></string-name> <etal>et al.</etal></person-group> (<year>2021</year>). <article-title>Gene co-expression modules integrated with immunoscore predicts survival of non-small cell lung cancer</article-title>. <source>Cancer Treatment and Research Communications</source> <volume>26</volume>: <fpage>100297</fpage>. DOI <pub-id pub-id-type="doi">10.1016/j.ctarc.2020.100297</pub-id>.</mixed-citation></ref>
<ref id="ref-29"><label>Lin <italic>et al</italic>. (2019)</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Lin</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Xu</surname> <given-names>J</given-names></string-name>, <string-name><surname>Lan</surname> <given-names>H</given-names></string-name></person-group> (<year>2019</year>). <article-title>Tumor-associated macrophages in tumor metastasis: Biological roles and clinical therapeutic applications</article-title>. <source>Journal of Hematology &#x0026; Oncology</source> <volume>12</volume>: <fpage>76</fpage>. DOI <pub-id pub-id-type="doi">10.1186/s13045-019-0760-3</pub-id>.</mixed-citation></ref>
<ref id="ref-30"><label>Lin <italic>et al</italic>. (2012)</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Lin</surname> <given-names>ZY</given-names></string-name>, <string-name><surname>Chuang</surname> <given-names>YH</given-names></string-name>, <string-name><surname>Chuang</surname> <given-names>WL</given-names></string-name></person-group> (<year>2012</year>). <article-title>Cancer-associated fibroblasts up-regulate CCL2, CCL26, IL6 and LOXL2 genes related to promotion of cancer progression in hepatocellular carcinoma cells</article-title>. <source>Biomedicine &#x0026; Pharmacotherapy</source> <volume>66</volume>: <fpage>525</fpage>&#x2013;<lpage>529</lpage>. DOI <pub-id pub-id-type="doi">10.1016/j.biopha.2012.02.001</pub-id>.</mixed-citation></ref>
<ref id="ref-31"><label>Liu and He (2020)</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Liu</surname> <given-names>J</given-names></string-name>, <string-name><surname>He</surname> <given-names>Z</given-names></string-name></person-group> (<year>2020</year>). <article-title>Small DNA methylation, big player in plant abiotic stress responses and memory</article-title>. <source>Frontiers in Plant Science</source> <volume>11</volume>: <fpage>595603</fpage>. DOI <pub-id pub-id-type="doi">10.3389/fpls.2020.595603</pub-id>.</mixed-citation></ref>
<ref id="ref-32"><label>Luo et al. (2020)</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Luo</surname> <given-names>H</given-names></string-name>, <string-name><surname>Zhao</surname> <given-names>Q</given-names></string-name>, <string-name><surname>Wei</surname> <given-names>W</given-names></string-name>, <string-name><surname>Zheng</surname> <given-names>L</given-names></string-name>, <string-name><surname>Yi</surname> <given-names>S</given-names></string-name> <etal>et al.</etal></person-group> (<year>2020</year>). <article-title>Circulating tumor DNA methylation profiles enable early diagnosis, prognosis prediction, and screening for colorectal cancer</article-title>. <source>Science Translational Medicine</source> <volume>12</volume>: <fpage>556</fpage>. DOI <pub-id pub-id-type="doi">10.1126/scitranslmed.aax7533</pub-id>.</mixed-citation></ref>
<ref id="ref-33"><label>Malouff et al. (2020)</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Malouff</surname> <given-names>TD</given-names></string-name>, <string-name><surname>Vallow</surname> <given-names>LA</given-names></string-name>, <string-name><surname>Seneviratne</surname> <given-names>D</given-names></string-name>, <string-name><surname>Mahajan</surname> <given-names>A</given-names></string-name>, <string-name><surname>Foote</surname> <given-names>RL</given-names></string-name> <etal>et al.</etal></person-group> (<year>2020</year>). <article-title>Estimating the number of patients eligible for carbon ion radiotherapy in the United States</article-title>. <source>International Journal of Particle Therapy</source> <volume>7</volume>: <fpage>31</fpage>&#x2013;<lpage>41</lpage>. DOI <pub-id pub-id-type="doi">10.14338/IJPT-19-00079.1</pub-id>.</mixed-citation></ref>
<ref id="ref-34"><label>Mastrella <italic>et al</italic>. (2019)</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Mastrella</surname> <given-names>G</given-names></string-name>, <string-name><surname>Hou</surname> <given-names>M</given-names></string-name>, <string-name><surname>Li</surname> <given-names>M</given-names></string-name>, <string-name><surname>Stoecklein</surname> <given-names>VM</given-names></string-name>, <string-name><surname>Zdouc</surname> <given-names>N</given-names></string-name> <etal>et al.</etal></person-group> (<year>2019</year>). <article-title>Targeting APLN/APLNR improves antiangiogenic efficiency and blunts proinvasive side effects of VEGFA/VEGFR2 blockade in glioblastoma</article-title>. <source>Cancer Research</source> <volume>79</volume>: <fpage>2298</fpage>&#x2013;<lpage>2313</lpage>. DOI <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-18-0881</pub-id>.</mixed-citation></ref>
<ref id="ref-35"><label>Miller et al. (2018)</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Miller</surname> <given-names>CN</given-names></string-name>, <string-name><surname>Dye</surname> <given-names>JA</given-names></string-name>, <string-name><surname>Schladweiler</surname> <given-names>MC</given-names></string-name>, <string-name><surname>Richards</surname> <given-names>JH</given-names></string-name>, <string-name><surname>Ledbetter</surname> <given-names>AD</given-names></string-name> <etal>et al.</etal></person-group> (<year>2018</year>). <article-title>Acute inhalation of ozone induces DNA methylation of apelin in lungs of Long-Evans rats</article-title>. <source>Inhalation Toxicology</source> <volume>30</volume>: <fpage>178</fpage>&#x2013;<lpage>186</lpage>. DOI <pub-id pub-id-type="doi">10.1080/08958378.2018.1483984</pub-id>.</mixed-citation></ref>
<ref id="ref-36"><label>Mishra et al. (2015)</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Mishra</surname> <given-names>A</given-names></string-name>, <string-name><surname>Kohli</surname> <given-names>S</given-names></string-name>, <string-name><surname>Dua</surname> <given-names>S</given-names></string-name>, <string-name><surname>Thinlas</surname> <given-names>T</given-names></string-name>, <string-name><surname>Mohammad</surname> <given-names>G</given-names></string-name> <etal>et al.</etal></person-group> (<year>2015</year>). <article-title>Genetic differences and aberrant methylation in the apelin system predict the risk of high-altitude pulmonary edema</article-title>. <source>Proceedings of the National Academy of Sciences of the United States of America</source> <volume>112</volume>: <fpage>6134</fpage>&#x2013;<lpage>6139</lpage>. DOI <pub-id pub-id-type="doi">10.1073/pnas.1422759112</pub-id>.</mixed-citation></ref>
<ref id="ref-37"><label>Mou et al. (2020)</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Mou</surname> <given-names>MA</given-names></string-name>, <string-name><surname>Keya</surname> <given-names>NA</given-names></string-name>, <string-name><surname>Islam</surname> <given-names>M</given-names></string-name>, <string-name><surname>Hossain</surname> <given-names>MJ</given-names></string-name>, <string-name><surname>Al</surname> <given-names>HM</given-names></string-name> <etal>et al.</etal></person-group> (<year>2020</year>). <article-title>Validation of CSN1S1 transcriptional expression, promoter methylation, and prognostic power in breast cancer using independent datasets</article-title>. <source>Biochemistry and Biophysics Reports</source> <volume>24</volume>: <fpage>100867</fpage>. DOI <pub-id pub-id-type="doi">10.1016/j.bbrep.2020.100867</pub-id>.</mixed-citation></ref>
<ref id="ref-38"><label>Muto et al. (2014)</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Muto</surname> <given-names>J</given-names></string-name>, <string-name><surname>Shirabe</surname> <given-names>K</given-names></string-name>, <string-name><surname>Yoshizumi</surname> <given-names>T</given-names></string-name>, <string-name><surname>Ikegami</surname> <given-names>T</given-names></string-name>, <string-name><surname>Aishima</surname> <given-names>S</given-names></string-name> <etal>et al.</etal></person-group> (<year>2014</year>). <article-title>The apelin-APJ system induces tumor arteriogenesis in hepatocellular carcinoma</article-title>. <source>Anticancer Research</source> <volume>34</volume>: <fpage>5313</fpage>&#x2013;<lpage>5320</lpage>.</mixed-citation></ref>
<ref id="ref-39"><label>Ondo et al. (2021)</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ondo</surname> <given-names>K</given-names></string-name>, <string-name><surname>Isono</surname> <given-names>M</given-names></string-name>, <string-name><surname>Nakano</surname> <given-names>M</given-names></string-name>, <string-name><surname>Hashiba</surname> <given-names>S</given-names></string-name>, <string-name><surname>Fukami</surname> <given-names>T</given-names></string-name> <etal>et al.</etal></person-group> (<year>2021</year>). <article-title>The N(6)-methyladenosine modification posttranscriptionally regulates hepatic UGT2B7 expression</article-title>. <source>Biochemical Pharmacology</source> <volume>189</volume>: <fpage>114402</fpage>. DOI <pub-id pub-id-type="doi">10.1016/j.bcp.2020.114402</pub-id>.</mixed-citation></ref>
<ref id="ref-40"><label>Picault et al. (2014)</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Picault</surname> <given-names>FX</given-names></string-name>, <string-name><surname>Chaves-Almagro</surname> <given-names>C</given-names></string-name>, <string-name><surname>Projetti</surname> <given-names>F</given-names></string-name>, <string-name><surname>Prats</surname> <given-names>H</given-names></string-name>, <string-name><surname>Masri</surname> <given-names>B</given-names></string-name> <etal>et al.</etal></person-group> (<year>2014</year>). <article-title>Tumour co-expression of apelin and its receptor is the basis of an autocrine loop involved in the growth of colon adenocarcinomas</article-title>. <source>European Journal of Cancer</source> <volume>50</volume>: <fpage>663</fpage>&#x2013;<lpage>674</lpage>. DOI <pub-id pub-id-type="doi">10.1016/j.ejca.2013.11.017</pub-id>.</mixed-citation></ref>
<ref id="ref-64"><label>Poureau and Metges (2021)</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Poureau</surname><given-names>P</given-names></string-name>, <string-name><surname>Metges</surname><given-names>J</given-names></string-name></person-group>(<year>2021</year>). <article-title>Fundamentals of Digestive Cancers Immunology, Especially Gastric and Hepatocellular CarcinomasFondamentaux de l&#x2019;immunologie des Cancers Digestifs (Gastriques et H&#x00E9;patocellulaires)</article-title>. <source>Oncologie</source> <bold>23</bold>: <fpage>47</fpage>&#x2013;<lpage>59</lpage>. DOI <pub-id pub-id-type="doi">10.32604/Oncologie.2021.15525</pub-id>.</mixed-citation></ref>
<ref id="ref-41"><label>Podgorska et al. (2018)</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Podgorska</surname> <given-names>M</given-names></string-name>, <string-name><surname>Pietraszek-Gremplewicz</surname> <given-names>K</given-names></string-name>, <string-name><surname>Nowak</surname> <given-names>D</given-names></string-name></person-group> (<year>2018</year>). <article-title>Apelin effects migration and invasion abilities of colon cancer cells</article-title>. <source>Cells</source> <volume>7</volume>: <fpage>113</fpage>. DOI <pub-id pub-id-type="doi">10.3390/cells7080113</pub-id>.</mixed-citation></ref>
<ref id="ref-42"><label>Ran et al. (2021)</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ran</surname> <given-names>J</given-names></string-name>, <string-name><surname>Li</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Liu</surname> <given-names>L</given-names></string-name>, <string-name><surname>Zhu</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Ni</surname> <given-names>Y</given-names></string-name> <etal>et al.</etal></person-group> (<year>2021</year>). <article-title>Apelin enhances biological functions in lung cancer A549 cells by downregulating exosomal miR-15a-5p</article-title>. <source>Carcinogenesis</source> <volume>42</volume>: <fpage>243</fpage>&#x2013;<lpage>253</lpage>. DOI <pub-id pub-id-type="doi">10.1093/carcin/bgaa089</pub-id>.</mixed-citation></ref>
<ref id="ref-43"><label>Rawat et al. (2018)</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Rawat</surname> <given-names>D</given-names></string-name>, <string-name><surname>Shrivastava</surname> <given-names>S</given-names></string-name>, <string-name><surname>Naik</surname> <given-names>RA</given-names></string-name>, <string-name><surname>Chhonker</surname> <given-names>SK</given-names></string-name>, <string-name><surname>Mehrotra</surname> <given-names>A</given-names></string-name> <etal>et al.</etal></person-group> (<year>2018</year>). <article-title>An overview of natural plant products in the treatment of hepatocellular carcinoma</article-title>. <source>Anti-cancer Agents in Medicinal Chemistry</source> <volume>18</volume>: <fpage>1838</fpage>&#x2013;<lpage>1859</lpage>. DOI <pub-id pub-id-type="doi">10.2174/1871520618666180604085612</pub-id>.</mixed-citation></ref>
<ref id="ref-44"><label>Rohr-Udilova <italic>et al</italic>. (2018)</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Rohr-Udilova</surname> <given-names>N</given-names></string-name>, <string-name><surname>Klinglmuller</surname> <given-names>F</given-names></string-name>, <string-name><surname>Schulte-Hermann</surname> <given-names>R</given-names></string-name>, <string-name><surname>Stift</surname> <given-names>J</given-names></string-name>, <string-name><surname>Herac</surname> <given-names>M</given-names></string-name> <etal>et al.</etal></person-group> (<year>2018</year>). <article-title>Deviations of the immune cell landscape between healthy liver and hepatocellular carcinoma</article-title>. <source>Science Reports</source> <volume>8</volume>: <fpage>6220</fpage>. DOI <pub-id pub-id-type="doi">10.1038/s41598-018-24437-5</pub-id>.</mixed-citation></ref>
<ref id="ref-45"><label>Seal <italic>et al</italic>. (2020)</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Seal</surname> <given-names>DB</given-names></string-name>, <string-name><surname>Das</surname> <given-names>V</given-names></string-name>, <string-name><surname>Goswami</surname> <given-names>S</given-names></string-name>, <string-name><surname>De</surname> <given-names>RK</given-names></string-name></person-group> (<year>2020</year>). <article-title>Estimating gene expression from DNA methylation and copy number variation: A deep learning regression model for multi-omics integration</article-title>. <source>Genomics</source> <volume>112</volume>: <fpage>2833</fpage>&#x2013;<lpage>2841</lpage>. DOI <pub-id pub-id-type="doi">10.1016/j.ygeno.2020.03.021</pub-id>.</mixed-citation></ref>
<ref id="ref-46"><label>Sharma et al. (2020)</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Sharma</surname> <given-names>A</given-names></string-name>, <string-name><surname>Sharma</surname> <given-names>KL</given-names></string-name>, <string-name><surname>Bansal</surname> <given-names>C</given-names></string-name>, <string-name><surname>Kumar</surname> <given-names>A</given-names></string-name></person-group> (<year>2020</year>). <article-title>Updates on &#x201C;Cancer Genomics and Epigenomics&#x201D;</article-title>. <source>World Journal of Clinical Oncology</source> <volume>11</volume>: <fpage>890</fpage>&#x2013;<lpage>897</lpage>. DOI <pub-id pub-id-type="doi">10.5306/wjco.v11.i11.890</pub-id>.</mixed-citation></ref>
<ref id="ref-47"><label>Tian et al. (2015)</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Tian</surname> <given-names>F</given-names></string-name>, <string-name><surname>Zhou</surname> <given-names>P</given-names></string-name>, <string-name><surname>Kang</surname> <given-names>W</given-names></string-name>, <string-name><surname>Luo</surname> <given-names>L</given-names></string-name>, <string-name><surname>Fan</surname> <given-names>X</given-names></string-name> <etal>et al.</etal></person-group> (<year>2015</year>). <article-title>The small-molecule inhibitor selectivity between IKKalpha and IKKbeta kinases in NF-kappaB signaling pathway</article-title>. <source>Journal of Receptor and Signal Transduction</source> <volume>35</volume>: <fpage>307</fpage>&#x2013;<lpage>318</lpage>. DOI <pub-id pub-id-type="doi">10.3109/10799893.2014.980950</pub-id>.</mixed-citation></ref>
<ref id="ref-48"><label>Topalian <italic>et al</italic>. (2016)</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Topalian</surname> <given-names>SL</given-names></string-name>, <string-name><surname>Taube</surname> <given-names>JM</given-names></string-name>, <string-name><surname>Anders</surname> <given-names>RA</given-names></string-name>, <string-name><surname>Pardoll</surname> <given-names>DM</given-names></string-name></person-group> (<year>2016</year>). <article-title>Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy</article-title>. <source>Nature Reviews Cancer</source> <volume>16</volume>: <fpage>275</fpage>&#x2013;<lpage>287</lpage>. DOI <pub-id pub-id-type="doi">10.1038/nrc.2016.36</pub-id>.</mixed-citation></ref>
<ref id="ref-63"><label>Wang <italic>et al</italic>. (2021)</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wang</surname><given-names>Z</given-names></string-name>,<string-name> <surname>He</surname><given-names>Y</given-names></string-name>, <string-name><surname>Song</surname><given-names>Y</given-names></string-name>, <string-name><surname>Wang</surname><given-names>Y</given-names></string-name>,<string-name> <surname>Chen</surname><given-names>F</given-names></string-name></person-group>(<year>2021</year>). <article-title>MicroRNA in HCC: Biomarkers and Therapeutic Targets</article-title>. <source>Oncologie</source><bold>23</bold>: <fpage>177</fpage>&#x2013;<lpage>184</lpage>. DOI <pub-id pub-id-type="doi">10.32604/Oncologie.2021.014773</pub-id>.</mixed-citation></ref>
<ref id="ref-49"><label>Wang et al. (2020a)</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wang</surname> <given-names>R</given-names></string-name>, <string-name><surname>Zhao</surname> <given-names>H</given-names></string-name>, <string-name><surname>Zhang</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Zhu</surname> <given-names>H</given-names></string-name>, <string-name><surname>Su</surname> <given-names>Q</given-names></string-name> <etal>et al.</etal></person-group> (<year>2020a</year>). <article-title>Identification of MicroRNA-92a-3p as an essential regulator of tubular epithelial cell pyroptosis by targeting Nrf1 via HO-1</article-title>. <source>Frontiers in Genetics</source> <volume>11</volume>: <fpage>616947</fpage>. DOI <pub-id pub-id-type="doi">10.3389/fgene.2020.616947</pub-id>.</mixed-citation></ref>
<ref id="ref-50"><label>Wang et al. (2020b)</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wang</surname> <given-names>X</given-names></string-name>, <string-name><surname>Liu</surname> <given-names>X</given-names></string-name>, <string-name><surname>Song</surname> <given-names>Z</given-names></string-name>, <string-name><surname>Shen</surname> <given-names>X</given-names></string-name>, <string-name><surname>Lu</surname> <given-names>S</given-names></string-name> <etal>et al.</etal></person-group> (<year>2020b</year>). <article-title>Emerging roles of APLN and APELA in the physiology and pathology of the female reproductive system</article-title>. <source>PeerJ</source> <volume>8</volume>: <fpage>e10245</fpage>. DOI <pub-id pub-id-type="doi">10.7717/peerj.10245</pub-id>.</mixed-citation></ref>
<ref id="ref-51"><label>Wang et al. (2020c)</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wang</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Zhang</surname> <given-names>X</given-names></string-name>, <string-name><surname>Xiao</surname> <given-names>X</given-names></string-name>, <string-name><surname>Zhang</surname> <given-names>FR</given-names></string-name>, <string-name><surname>Yan</surname> <given-names>X</given-names></string-name> <etal>et al.</etal></person-group> (<year>2020c</year>). <article-title>Accurately estimating the length distributions of genomic micro-satellites by tumor purity deconvolution</article-title>. <source>BMC Bioinformatics</source> <volume>21</volume>: <fpage>82</fpage>. DOI <pub-id pub-id-type="doi">10.1186/s12859-020-3349-5</pub-id>.</mixed-citation></ref>
<ref id="ref-52"><label>Wang and Zhang (2020)</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wang</surname> <given-names>YL</given-names></string-name>, <string-name><surname>Zhang</surname> <given-names>YY</given-names></string-name></person-group> (<year>2020</year>). <article-title>cg04448376, cg24387542, cg08548498, and cg14621323 as a novel signature to predict prognosis in kidney renal papillary cell carcinoma</article-title>. <source>BioMed Research International</source> <volume>2020</volume>: <fpage>4854390</fpage>. DOI <pub-id pub-id-type="doi">10.1155/2020/4854390</pub-id>.</mixed-citation></ref>
<ref id="ref-53"><label>Wildes <italic>et al</italic>. (2020)</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wildes</surname> <given-names>TJ</given-names></string-name>, <string-name><surname>Dyson</surname> <given-names>KA</given-names></string-name>, <string-name><surname>Francis</surname> <given-names>C</given-names></string-name>, <string-name><surname>Wummer</surname> <given-names>B</given-names></string-name>, <string-name><surname>Yang</surname> <given-names>C</given-names></string-name> <etal>et al.</etal></person-group> (<year>2020</year>). <article-title>Immune escape after adoptive T-cell therapy for malignant gliomas</article-title>. <source>Clinical Cancer Research</source> <volume>26</volume>: <fpage>5689</fpage>&#x2013;<lpage>5700</lpage>. DOI <pub-id pub-id-type="doi">10.1158/1078-0432.CCR-20-1065</pub-id>.</mixed-citation></ref>
<ref id="ref-54"><label>Wolf-Dennen <italic>et al</italic>. (2020)</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wolf-Dennen</surname> <given-names>K</given-names></string-name>, <string-name><surname>Gordon</surname> <given-names>N</given-names></string-name>, <string-name><surname>Kleinerman</surname> <given-names>ES</given-names></string-name></person-group> (<year>2020</year>). <article-title>Exosomal communication by metastatic osteosarcoma cells modulates alveolar macrophages to an M2 tumor-promoting phenotype and inhibits tumoricidal functions</article-title>. <source>OncoImmunology</source> <volume>9</volume>: <fpage>1747677</fpage>. DOI <pub-id pub-id-type="doi">10.1080/2162402X.2020.1747677</pub-id>.</mixed-citation></ref>
<ref id="ref-55"><label>Wu et al. (2020)</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wu</surname> <given-names>J</given-names></string-name>, <string-name><surname>Mamidi</surname> <given-names>T</given-names></string-name>, <string-name><surname>Zhang</surname> <given-names>L</given-names></string-name>, <string-name><surname>Hicks</surname> <given-names>C</given-names></string-name></person-group> (<year>2020</year>). <article-title>Unraveling the genomic-epigenomic interaction landscape in triple negative and non-triple negative breast cancer</article-title>. <source>Cancers</source> <volume>12</volume>: <fpage>1559</fpage>. DOI <pub-id pub-id-type="doi">10.3390/cancers12061559</pub-id>.</mixed-citation></ref>
<ref id="ref-57"><label>Xu <italic>et al</italic>. (2017)</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Xu</surname> <given-names>RH</given-names></string-name>, <string-name><surname>Wei</surname> <given-names>W</given-names></string-name>, <string-name><surname>Krawczyk</surname> <given-names>M</given-names></string-name>, <string-name><surname>Wang</surname> <given-names>W</given-names></string-name>, <string-name><surname>Luo</surname> <given-names>H</given-names></string-name> <etal>et al.</etal></person-group> (<year>2017</year>). <article-title>Circulating tumour DNA methylation markers for diagnosis and prognosis of hepatocellular carcinoma</article-title>. <source>Nature Materials</source> <volume>16</volume>: <fpage>1155</fpage>&#x2013;<lpage>1161</lpage>. DOI <pub-id pub-id-type="doi">10.1038/nmat4997</pub-id>.</mixed-citation></ref>
<ref id="ref-58"><label>Yang et al. (2019)</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Yang</surname> <given-names>L</given-names></string-name>, <string-name><surname>Li</surname> <given-names>YL</given-names></string-name>, <string-name><surname>Li</surname> <given-names>XQ</given-names></string-name>, <string-name><surname>Zhang</surname> <given-names>Z</given-names></string-name></person-group> (<year>2019</year>). <article-title>Corrigendum to &#x201C;High apelin level indicates a poor prognostic factor in muscle-invasive bladder cancer&#x201D;</article-title>. <source>Disease Markers</source> <volume>2019</volume>: <fpage>5974238</fpage>. DOI <pub-id pub-id-type="doi">10.1155/2019/5974238</pub-id>.</mixed-citation></ref>
<ref id="ref-60"><label>Yang et al. (2014)</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Yang</surname> <given-names>X</given-names></string-name>, <string-name><surname>Yang</surname> <given-names>J</given-names></string-name>, <string-name><surname>Chu</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Xue</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Xuan</surname> <given-names>D</given-names></string-name> <etal>et al.</etal></person-group> (<year>2014</year>). <article-title>T follicular helper cells and regulatory B cells dynamics in systemic lupus erythematosus</article-title>. <source>PLoS One</source> <volume>9</volume>: <fpage>e88441</fpage>. DOI <pub-id pub-id-type="doi">10.1371/journal.pone.0088441</pub-id>.</mixed-citation></ref>
<ref id="ref-61"><label>Yin et al. (2019)</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Yin</surname> <given-names>L</given-names></string-name>, <string-name><surname>He</surname> <given-names>N</given-names></string-name>, <string-name><surname>Chen</surname> <given-names>C</given-names></string-name>, <string-name><surname>Zhang</surname> <given-names>N</given-names></string-name>, <string-name><surname>Lin</surname> <given-names>Y</given-names></string-name> <etal>et al.</etal></person-group> (<year>2019</year>). <article-title>Identification of novel blood-based HCC-specific diagnostic biomarkers for human hepatocellular carcinoma</article-title>. <source>Artificial Cells, Nanomedicine, and Biotechnology</source> <volume>47</volume>: <fpage>1908</fpage>&#x2013;<lpage>1916</lpage>. DOI <pub-id pub-id-type="doi">10.1080/21691401.2019.1613421</pub-id>.</mixed-citation></ref>
<ref id="ref-62"><label>Zuurbier <italic>et al</italic>. (2017)</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zuurbier</surname> <given-names>L</given-names></string-name>, <string-name><surname>Rahman</surname> <given-names>A</given-names></string-name>, <string-name><surname>Cordes</surname> <given-names>M</given-names></string-name>, <string-name><surname>Scheick</surname> <given-names>J</given-names></string-name>, <string-name><surname>Wong</surname> <given-names>TJ</given-names></string-name> <etal>et al.</etal></person-group> (<year>2017</year>). <article-title>Apelin: A putative novel predictive biomarker for bevacizumab response in colorectal cancer</article-title>. <source>Oncotarget</source> <volume>8</volume>: <fpage>42949</fpage>&#x2013;<lpage>42961</lpage>. DOI <pub-id pub-id-type="doi">10.18632/oncotarget.17306</pub-id>.</mixed-citation></ref>
</ref-list>
</back>
</article>